
Early study finds new lymphoma drug effective
Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.
Michigan Medicine is renowned for groundbreaking clinical, basic science and medical educational research, with nearly 7,000 papers published annually by faculty and trainees. Here, Lab Notes highlights a selection of those articles in addition to ones covered as stories on the Michigan Health Lab blog.
Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.
The “Wikiguideline” approach establishes recommendations only when high-quality, hypothesis-confirming evidence is available.
The findings could lead to repurposing drugs for patients with the sometimes-fatal condition.
Some pharmacies participated in the standing order but did not have any naloxone available on the shelf.
Discovery paves the way for new drug targets.
Study points to role of primary care received outside an Accountable Care Organization’s network, and the importance of coordination and access